Tags

Type your tag names separated by a space and hit enter

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Clin Infect Dis. 2008 Oct 15; 47(8):1093-101.CI

Abstract

BACKGROUND

In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on immunological recovery remains uncertain.

METHODS

During January 1996 through December 2004 [corrected] all patients in the Swiss HIV Cohort were included if they received the first combination antiretroviral therapy (cART) and had known baseline CD4(+) T cell counts and HIV-1 RNA values (n = 3293). For follow-up, we used the Swiss HIV Cohort Study database update of May 2007 [corrected] The mean (+/-SD) duration of follow-up was 26.8 +/- 20.5 months. The follow-up time was limited to the duration of the first cART. CD4(+) T cell recovery was analyzed in 3 different treatment groups: nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4(+) T cell count in the 3 treatment groups after the initiation of cART.

RESULTS

Two thousand five hundred ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%) initiated an NNRTI regimen, and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4(+) T cell count increases at 48 months were as follows: in the nonboosted-PI group, from 210 to 520 cells/muL; in the NNRTI group, from 220 to 475 cells/muL; and in the boosted-PI group, from 168 to 511 cells/muL. In a multivariate analysis, the treatment group did not affect the response of CD4(+) T cells; however, increased age, pretreatment with nucleoside reverse-transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers for Disease Control and Prevention stage C infection, lower baseline CD4(+) T cell count, and lower baseline HIV-1 RNA level were risk factors for smaller increases in CD4(+) T cell count.

CONCLUSION

CD4(+) T cell recovery was similar in patients receiving nonboosted PI-, NNRTI-, and boosted PI-based cART.

Authors+Show Affiliations

Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18783328

Citation

Khanna, Nina, et al. "CD4+ T Cell Count Recovery in HIV Type 1-infected Patients Is Independent of Class of Antiretroviral Therapy." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 47, no. 8, 2008, pp. 1093-101.
Khanna N, Opravil M, Furrer H, et al. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis. 2008;47(8):1093-101.
Khanna, N., Opravil, M., Furrer, H., Cavassini, M., Vernazza, P., Bernasconi, E., Weber, R., Hirschel, B., Battegay, M., & Kaufmann, G. R. (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 47(8), 1093-101. https://doi.org/10.1086/592113
Khanna N, et al. CD4+ T Cell Count Recovery in HIV Type 1-infected Patients Is Independent of Class of Antiretroviral Therapy. Clin Infect Dis. 2008 Oct 15;47(8):1093-101. PubMed PMID: 18783328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. AU - Khanna,Nina, AU - Opravil,Milos, AU - Furrer,Hansjakob, AU - Cavassini,Matthias, AU - Vernazza,Pietro, AU - Bernasconi,Enos, AU - Weber,Rainer, AU - Hirschel,Bernard, AU - Battegay,Manuel, AU - Kaufmann,Gilbert R, AU - ,, PY - 2008/9/12/pubmed PY - 2008/10/24/medline PY - 2008/9/12/entrez SP - 1093 EP - 101 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 47 IS - 8 N2 - BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on immunological recovery remains uncertain. METHODS: During January 1996 through December 2004 [corrected] all patients in the Swiss HIV Cohort were included if they received the first combination antiretroviral therapy (cART) and had known baseline CD4(+) T cell counts and HIV-1 RNA values (n = 3293). For follow-up, we used the Swiss HIV Cohort Study database update of May 2007 [corrected] The mean (+/-SD) duration of follow-up was 26.8 +/- 20.5 months. The follow-up time was limited to the duration of the first cART. CD4(+) T cell recovery was analyzed in 3 different treatment groups: nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4(+) T cell count in the 3 treatment groups after the initiation of cART. RESULTS: Two thousand five hundred ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%) initiated an NNRTI regimen, and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4(+) T cell count increases at 48 months were as follows: in the nonboosted-PI group, from 210 to 520 cells/muL; in the NNRTI group, from 220 to 475 cells/muL; and in the boosted-PI group, from 168 to 511 cells/muL. In a multivariate analysis, the treatment group did not affect the response of CD4(+) T cells; however, increased age, pretreatment with nucleoside reverse-transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers for Disease Control and Prevention stage C infection, lower baseline CD4(+) T cell count, and lower baseline HIV-1 RNA level were risk factors for smaller increases in CD4(+) T cell count. CONCLUSION: CD4(+) T cell recovery was similar in patients receiving nonboosted PI-, NNRTI-, and boosted PI-based cART. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/18783328/CD4+_T_cell_count_recovery_in_HIV_type_1_infected_patients_is_independent_of_class_of_antiretroviral_therapy_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/592113 DB - PRIME DP - Unbound Medicine ER -